Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
19 hedge funds and large institutions have $2.05M invested in Aridis Pharmaceuticals Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 6 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
3.12% less ownership
Funds ownership: 13.68% → 10.56% (-3.1%)
14% less funds holding
Funds holding: 22 → 19 (-3)
39% less capital invested
Capital invested by funds: $3.38M → $2.05M (-$1.33M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$13.4K |
| 2 |
BRWM
B. Riley Wealth Management
Memphis,
Tennessee
|
+$12.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.3K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$8.67K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
-$42K |
| 2 |
BlackRock
New York
|
-$22.5K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$21K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$16K |
ARDS Hedge Fund Activity: Q2 2022 in Review
19 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q2 2022, worth a combined $2.05M — down 39% from $3.38M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ARDS and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $13.4K. The largest seller was Perritt Capital Management, exiting entirely with an estimated $42K sold.
- 19 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q2 2022, down from 22 in Q1 2022.
- Funds reported $2.05M of Aridis Pharmaceuticals Inc. Common Stock stock for Q2 2022, down 39% quarter-over-quarter.
- 3 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of -3 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $13.4K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q2 2022 was Perritt Capital Management, an estimated $42K sold.
Based on aggregated 13F filings for Q2 2022.